<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>LLY on Deep Analyst AI</title><link>https://deepanalyst.ai/tags/LLY/</link><description>Recent content in LLY on Deep Analyst AI</description><generator>Hugo -- gohugo.io</generator><language>en-us</language><lastBuildDate>Wed, 04 Feb 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://deepanalyst.ai/tags/LLY/rss.xml" rel="self" type="application/rss+xml"/><item><title>The $4.5 Billion TSA PreCheck: How Lilly Just Bought the FDA’s VIP Lane</title><link>https://deepanalyst.ai/posts/2026/02/lly-4-5-billion-tsa-precheck-how-lilly-just-bought-fda-s-vip-lane/</link><pubDate>Wed, 04 Feb 2026 00:00:00 +0000</pubDate><guid>https://deepanalyst.ai/posts/2026/02/lly-4-5-billion-tsa-precheck-how-lilly-just-bought-fda-s-vip-lane/</guid><description>The $4.5 Billion TSA PreCheck: How Lilly Just Bought the FDA’s VIP Lane For decades, &amp;ldquo;Made in America&amp;rdquo; was a cute marketing slogan for pickup trucks and craft beer, not a viable strategy for Big Pharma margins. But Eli Lilly (LLY) has decided to flip the script, treating the U.S. regulatory landscape less like a minefield and more like an exclusive country club. While the market sees a dull construction project in the cornfields, the smart money recognizes the real play: Lilly is dropping billions to effectively buy TSA PreCheck while its rivals are still taking off their belts and shoes in the general boarding line.</description></item></channel></rss>